COMPASS试验:肥胖与超重血管病患者中利伐沙班联合阿司匹林的效果
COMPASS试验二次分析纳入27,395例慢性冠心病或外周动脉疾病患者,按BMI和体重分层,评估利伐沙班2.5 mg每日两次联合阿司匹林100 mg/日对比阿司匹林单药的效果。结果显示联合治疗在不同BMI和体重范围内均一致降低心血管死亡、卒中或心肌梗死风险,出血、死亡和净临床获益亦一致,提示在试验纳入的体重和BMI范围内无需调整剂量。
要点
- 利伐沙班2.5 mg每日两次联合阿司匹林在不同BMI和体重患者中一致降低主要心血管事件。
- 出血、死亡和净临床获益在不同BMI和体重范围内表现一致。
- 在COMPASS试验纳入的体重和BMI范围内无需调整剂量。
核心结论
- 双通路抗血栓治疗的效果在不同BMI或体重下一致,提示在COMPASS试验纳入的体重和BMI范围内无需调整剂量。
- 更极端体重范围的问题仍需进一步研究。
研究设计与样本
- COMPASS试验的二次分析,纳入慢性冠心病或外周动脉疾病患者。
- 共随机化27,395例患者,其中正常BMI 6,459例(24%),超重12,047例(44%),肥胖8,701例(32%)。
- 按BMI分层:正常18.5≤BMI<25 kg/m2,超重25≤BMI<30 kg/m2,肥胖≥30 kg/m2;按体重分层:≤70 kg、70<体重≤90 kg、>90 kg,以及≤120 kg vs. >120 kg。
主要发现
- 主要终点心血管死亡、卒中或心肌梗死:正常BMI组利伐沙班联合阿司匹林3.5% vs. 阿司匹林5.0%,HR 0.73(95% CrI 0.58-0.90)。
- 超重组4.3% vs. 5.1%,HR 0.80(95% CrI 0.66-0.96);肥胖组4.2% vs. 6.1%,HR 0.71(95% CrI 0.57-0.86)。
- 体重≤70 kg组4.1% vs. 5.3%,HR 0.75(95% CrI 0.62-0.91);70<体重≤90 kg组4.1% vs. 5.3%,HR 0.76(95% CrI 0.65-0.89);>90 kg组4.2% vs. 5.7%,HR 0.74(95% CrI 0.61-0.90)。
- 出血、死亡和净临床获益在不同BMI或体重下一致。
关键数值与推荐
- 主要终点为心血管死亡、卒中或心肌梗死。
- 双通路抗血栓治疗为利伐沙班2.5 mg每日两次联合阿司匹林100 mg/日。
- 在COMPASS试验纳入的体重和BMI范围内无需调整剂量。
临床怎么用
- 对于慢性冠心病或外周动脉疾病患者,利伐沙班2.5 mg每日两次联合阿司匹林100 mg/日的疗效和安全性在不同BMI和体重范围内一致。
- 在COMPASS试验纳入的体重和BMI范围内,无需根据体重或BMI调整利伐沙班剂量。
局限性
- 为COMPASS试验的二次分析。
- 更极端体重范围的问题需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct oral anticoagulants are administered in fixed doses irrespective of body weight, but guidelines recommend against their use in patients with extremes of body weight. OBJECTIVES: This study determined the effects of dual-pathway inhibition antithrombotic regimen (rivaroxaban 2.5 mg twice daily plus aspirin 100 mg/day) compared with aspirin Halone across a range of patient body mass indexes (BMIs) and body weights. METHODS: This was a secondary analysis of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, which included patients with chronic coronary artery disease or peripheral artery disease. Efficacy and safety outcomes were studied in relation to BMI: (normal 18.5 ≤BMI <25 kg/m2, overweight 25 ≤BMI <30 kg/m2, obese ≥30 kg/m2) and body weight (≤70 kg, 70 < weight ≤90 kg, and >90 kg; as well as ≤120 kg vs. >120 kg). RESULTS: Among 27,395 randomized patients, 6,459 (24%) had normal BMI, 12,047 (44%) were overweight, and 8,701 (32%) were obese. The combination of rivaroxaban and aspirin compared with aspirin produced a consistent reduction in the primary outcome of cardiovascular death, stroke, or myocardial infarction, irrespective of BMI or body weight. For 18.5 ≤BMI <25 kg/m2: 3.5% vs. 5.0%; hazard ratio (HR): 0.73 (95% credible interval [CrI]: 0.58 to 0.90); 25 ≤ BMI <30 kg/m2: 4.3% vs. 5.1%; HR: 0.80 (95% CrI: 0.66 to 0.96); BMI ≥30 kg/m2: 4.2% vs. 6.1%; HR: 0.71 (95% CrI: 0.57 to 0.86). For body weight ≤70 kg: 4.1% vs. 5.3%; HR: 0.75 (95% CrI: 0.62 to 0.91); 70 < weight ≤90 kg: 4.1% vs. 5.3%; HR: 0.76 (95% CrI: 0.65 to 0.89); >90 kg: 4.2% vs. 5.7%; HR: 0.74 (95% CrI: 0.61 to 0.90). Effects on bleeding, mortality, and net clinical benefit were consistent irrespective of BMI or bodyweight. CONCLUSIONS: The effects of dual-pathway antithrombotic therapy are consistent irrespective of BMI or body weight, suggesting no need for dose adjustments in the ranges of weights and BMI of patients enrolled in the COMPASS trial. Further studies need to address this problem in relation to greater extremes of body weight. (Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease [COMPASS]; NCT01776424).
引用
- Guzik TJ, Ramasundarahettige C, Pogosova N, et al. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. J Am Coll Cardiol. 2021. PMID: 33538248. doi:10.1016/j.jacc.2020.11.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。